enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Alnylam Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Alnylam_Pharmaceuticals

   Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. [4]

3. Yvonne Greenstreet - Wikipedia

   en.wikipedia.org/wiki/Yvonne_Greenstreet

   Greenstreet became Alnylam's chief operating officer in 2016. In 2021, it was announced that John Maraganore would step down as Alnylam's CEO on 1 January 2022, and would be succeeded by Greenstreet. [1]

4. John Maraganore - Wikipedia

   en.wikipedia.org/wiki/John_Maraganore

   The fifth RNAi therapeutic medicine, AMVUTTRA, was approved in 2021. At Alnylam, he forged over 25 major partnerships with leading pharmaceutical and biotechnology companies, raised over $7.5 billion to fund the company’s research, development, manufacturing, and commercialization activities, and built $25 billion in market capitalization value.

5. Alnylam's Biggest Opportunities - AOL

   www.aol.com/news/2013-10-01-alnylams-biggest...

   Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a biotech company developing a new class of medications based on RNAi technology, have soared 250% since the start of 2013. Why are investors so ...

6. The Medicines Company Licenses Alnylam's Cholesterol Program

   www.aol.com/news/2013-02-04-the-medicines...

   The Medicines Company has licensed Alnylam Pharmaceuticals' cholesterol-lowering ALN-PCS RNAi therapeutic program, the companies announced today. Alnylam is due $25 million upfront from The ...

7. Alnylam Pharmaceuticals, Inc.: Big Pharma Loves This Stock - AOL

   www.aol.com/news/2014-01-13-alnylam...

   If orphan drugs and rare diseases were a theme of 2013's biotech bull market, then today's $700 million deal between Alnylam and Sanofi is a sign it isn't slowing down anytime soon. Alynlam wasn't ...

8. Amy Schulman - Wikipedia

   en.wikipedia.org/wiki/Amy_Schulman

   Amy Weinfeld Schulman is an American healthcare biotech venture capitalist, trained as a lawyer, who serves as a managing partner at Polaris Partners. [1] [2] [3] She focuses on investing in healthcare companies and early-stage biotech start-ups.

9. Alnylam Pharmaceuticals, Inc.: The Best Performing Biotechs ...

   www.aol.com/news/2013-12-26-alnylam...

   For premium support please call: 800-290-4726 more ways to reach us